JNJ - XBiotech: New Q1 2021 Clinical Announcement 9M 2020 Confirmed Short-Term Janssen Revenues 2022 Is Uncertain +28% Upside

• XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies.
• XBiotech's pipeline consists of 4 candidates with 3 in the pre-clinical phase. Starting 1-2Q 2021, XBiotech aims to re-enter the clinic with more than one new anti-IL-1a therapy.
• XBiotech made an interesting transition in 2019 with its first revenue streams starting Q1 2020 reaching $38.7M at 9M 2019 with $238M in cash, enough for 2-4 years of runway.
• XBiotech aims to disclose a long-anticipated progress update in Q1 2021 regarding new anti-IL-1? therapies that are being pushed into the clinic.
• In summary, the author projects conservatively XBiotech Inc. as a "buy" at a 2-year price target of $24.86 (+28% upside).

For further details see: